Table 5.
Adverse events in 3 groups during treatment.
| Group (n = 30) | Adverse events n (%) | No adverse events n (%) |
|---|---|---|
| NXAS | 1 (3.3) | 29 (96.7) |
| Zopiclone | 6 (20.0) | 24 (80.0) |
| Placebo | 0 (0.0) | 30 (100.0) |
| χ2 | 9.604 | |
| P-value | 0.008 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.